Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: THC stock price vs ABT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABT's multiple
Needs ABT P/E.
Implied fair value · at THC's multiple
Needs THC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TENET HEALTHCARE CORP · implied price per share
Bear
$105.38
Base
$143.97
Bull
$194.22
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HCA Healthcare, Inc.
THC vs HCA
UNIVERSAL HEALTH SERVICES INC
THC vs UHS
COMMUNITY HEALTH SYSTEMS INC
THC vs CYH
Encompass Health Corp
THC vs EHC
SELECT MEDICAL HOLDINGS CORP
THC vs SEM
Acadia Healthcare Company, Inc.
THC vs ACHC
Johnson & Johnson
THC vs JNJ
Medtronic plc
THC vs MDT
BECTON DICKINSON & CO
THC vs BDX
Thermo Fisher Scientific Inc.
THC vs TMO
DANAHER CORP /DE/
THC vs DHR
BOSTON SCIENTIFIC CORP
THC vs BSX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe THC can sustain its 24.2% ROIC while narrowing the margin and growth gap versus ABT, then THC looks attractive on a relative valuation basis because it trades at 16.4x earnings and 1.0x sales versus ABT’s 28.4x and 4.2x; otherwise, ABT’s premium is supported by better growth, margins, and balance-sheet quality.
THC trades at a steep discount to ABT on both earnings and sales-based multiples, with the largest gap in EV/EBITDA and P/S. The model’s implied price suggests significant upside, but the market is not paying ABT-like multiples for THC because the operating and quality profile is meaningfully weaker.
Supporting Metrics
